Compounding: Hamburg, Dems Look To Shift Spotlight Away From FDA As Hearing Looms
This article was originally published in The Pink Sheet Daily
Executive Summary
After a House subcommittee announces hearing focused on whether FDA could have prevented the meningitis outbreak at the New England Compounding Center, FDA commissioner and subcommittee Democrats write about apparent outside efforts to sidestep and delay compounder inspections.